Rx Stocks Suffer Medicare Hangover; Aventis Bid Fails To Spark Rally
Executive Summary
Aventis is winning the battle to persuade investors that it is worth more than Sanofi says, but the budding bidding war for the company has not been enough to cure Wall Street's aversion to pharmaceutical stocks
You may also be interested in...
GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through
GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S
GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through
GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S
Aventis Pushes For Novartis Merger: Evokes European Pride In French Talks
Aventis believes a merger with Novartis would be more beneficial to Europe's pharmaceutical industry than a deal with Sanofi, the company said April 5